Dean M. Wingerchuk

Active 1997–2024

88
Papers
31,213
Citations
66
h-index
88
i10-index

Citations

Citations per year for Dean M. Wingerchuk1990: 1 citations1999: 3 citations2000: 2 citations2001: 9 citations2002: 26 citations2003: 26 citations2004: 20 citations2005: 29 citations2006: 87 citations2007: 156 citations2008: 178 citations2009: 236 citations2010: 221 citations2011: 267 citations2012: 257 citations2013: 279 citations2014: 182 citations2015: 238 citations2016: 193 citations2017: 191 citations2018: 194 citations2019: 781 citations2020: 1,014 citations2021: 922 citations2022: 664 citations2023: 504 citations2024: 799 citations2025: 303 citations2026: 1 citations1991–1998: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,350 citing papers, 21.3% of this breakdownGermany: 537 citing papers, 8.5% of this breakdownUnited Kingdom: 525 citing papers, 8.3% of this breakdownChina: 391 citing papers, 6.2% of this breakdownItaly: 358 citing papers, 5.6% of this breakdownJapan: 287 citing papers, 4.5% of this breakdownFrance: 274 citing papers, 4.3% of this breakdownCanada: 244 citing papers, 3.8% of this breakdownSpain: 188 citing papers, 3% of this breakdownAustralia: 172 citing papers, 2.7% of this breakdownAustria: 170 citing papers, 2.7% of this breakdownSwitzerland: 152 citing papers, 2.4% of this breakdown
0%21.3%Other 26.7%

Fields

  • Medicine84.3%
  • Neuroscience5%
  • Biochemistry, Genetics and Molecular Biology4.9%
  • Immunology and Microbiology4.8%
  • Engineering0.3%
  • Materials Science0.2%
  • Other0.5%

Topics

  • Multiple Sclerosis Research Studies23.4%
  • Peripheral Neuropathies and Disorders13.5%
  • Systemic Lupus Erythematosus Research4.5%
  • Autoimmune Neurological Disorders and Treatments4.1%
  • Neuroinflammation and Neurodegeneration Mechanisms2.9%
  • Ocular Diseases and Behçet’s Syndrome1.8%
  • Other49.8%

Coauthors

All papers

Open in search
  1. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders

    Authors: , , , , , , , , , , , , , , , , , , - Neurology 2015 cited by 4,543

  2. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , - The Lancet 2019 cited by 717

  3. Eculizumab in Aquaporin-4–Positive Neuromyelitis Optica Spectrum Disorder

    Authors: , , , , , , , , , , , , , , - New England Journal of Medicine 2019 cited by 846

  4. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis

    Authors: , , , , , , , - The Lancet 2004 cited by 3,227

  5. Epidemiology of Neuromyelitis Optica Spectrum Disorder and Its Prevalence and Incidence Worldwide

    Authors: , , , , , , , , , , , , , , , - Frontiers in Neurology 2020 cited by 398

  6. The spectrum of neuromyelitis optica

    Authors: , , , , - The Lancet Neurology 2007 cited by 2,177

  7. Neuromyelitis Optica Spectrum Disorder

    Authors: , - New England Journal of Medicine 2022 cited by 196

  8. The contemporary spectrum of multiple sclerosis misdiagnosis

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Neurology 2016 cited by 324

  9. Association of MOG-IgG Serostatus With Relapse After Acute Disseminated Encephalomyelitis and Proposed Diagnostic Criteria for MOG-IgG–Associated Disorders

    Authors: , , , , , , , , , , , , , , , , , - JAMA Neurology 2018 cited by 407

  10. Myelin Oligodendrocyte Glycoprotein Antibody–Positive Optic Neuritis: Clinical Characteristics, Radiologic Clues, and Outcome

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - American Journal of Ophthalmology 2018 cited by 400

  11. The clinical course of neuromyelitis optica (Devic’s syndrome)

    Authors: , , , - Neurology 1999 cited by 1,815

  12. Multiple Sclerosis: Current and Emerging Disease-Modifying Therapies and Treatment Strategies

    Authors: , - Mayo Clinic Proceedings 2014 cited by 414

  13. Epidemiology of aquaporin‐4 autoimmunity and neuromyelitis optica spectrum

    Authors: , , , , , , , , , , , , , , , , - Annals of Neurology 2016 cited by 339

  14. Treatment of MOG antibody associated disorders: results of an international survey.

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , M. Apiwattankul, Jyh Yung Hor, S Viswanathan, Wei Qiu, Han Jo Kim, Ichiro Nakashima, Kazuo Fujihara, Sudarshini Ramanathan, Russell C. Dale, M. Boggild, Simon Broadley, M. A. Lana-Peixoto, Douglas Kazutoshi Sato, Sílvia Tenembaum, P. Cabré, Dean M. Wingerchuk, Brian G. Weinshenker, Benjamin Greenberg, Marcelo Matiello, Eric C. Klawiter, Jeffrey L. Bennett, Asya I. Wallach, Ilya Kister, Brenda Banwell, Anthony Traboulsee, Daniela Pohl, Jacqueline Palace, Maria Isabel Leite, Michael Levy, Romain Marignier, Tom Solomon, Ming Lim, Saif Huda, A. Jacob - 2020 cited by 138

  15. Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Hadas Stiebel‐Kalish, Sean J. Pittock - Neurology 2020 cited by 231

  16. Serum neurofilament light chain levels at attack predict post-attack disability worsening and are mitigated by inebilizumab: analysis of four potential biomarkers in neuromyelitis optica spectrum disorder

    Authors: , , , , , , , , , , , , , , , , , - Journal of Neurology Neurosurgery & Psychiatry 2023 cited by 45

  17. Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis

    Authors: , , , , , , , , , , - Brain 2007 cited by 714

  18. Cerebral enhancement in MOG antibody-associated disease

    Authors: , , , , , , , , , , , , , , , - Journal of Neurology Neurosurgery & Psychiatry 2023 cited by 31

  19. Estriol combined with glatiramer acetate for women with relapsing-remitting multiple sclerosis: a randomised, placebo-controlled, phase 2 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Neurology 2015 cited by 201

  20. Long‐Term Safety and Efficacy of Eculizumab in Aquaporin‐4 IgG‐Positive NMOSD

    Authors: , , , , , , , , , , , , , , - Annals of Neurology 2021 cited by 96

  21. Neuromyelitis Optica Brain Lesions Localized at Sites of High Aquaporin 4 Expression

    Authors: , , , , , - Archives of Neurology 2006 cited by 702

  22. Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension

    Authors: , , , , , , , , , , , , , - Multiple Sclerosis Journal 2021 cited by 78

  23. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study

    Authors: , , , , , , , - The Lancet Neurology 2013 cited by 394

  24. Smoking: effects on multiple sclerosis susceptibility and disease progression

    Authors: - Therapeutic Advances in Neurological Disorders 2011 cited by 187